Recombinant Human DGKE, N-His from ProteoGenix; catalogue ARO-P13651; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human DGKE (Diacylglycerol Kinase Epsilon) is a protein that plays a crucial role in the regulation of lipid signaling pathways. It is a member of the diacylglycerol kinase (DGK) family and is involved in the metabolism of diacylglycerol (DAG), a key intermediate in lipid metabolism. Recombinant Human DGKE is produced through recombinant DNA technology, making it a valuable tool for research and potential therapeutic applications.
Recombinant Human DGKE is a 105 kDa protein consisting of 930 amino acids. It contains two conserved domains, a catalytic domain and a regulatory domain. The catalytic domain is responsible for the enzymatic activity of DGKE, while the regulatory domain helps in the localization and regulation of the enzyme. The structure of Recombinant Human DGKE is highly conserved across different species, indicating its importance in cellular processes.
The main function of Recombinant Human DGKE is to phosphorylate DAG, converting it into phosphatidic acid (PA). This reaction is essential for the regulation of DAG levels, which in turn affects various cellular processes such as cell growth, differentiation, and apoptosis. Recombinant Human DGKE is also involved in the regulation of lipid signaling pathways, including the phosphoinositide 3-kinase (PI3K) and protein kinase C (PKC) pathways.
Recombinant Human DGKE has various applications in both research and potential therapeutic areas. Some of the major applications are:
Recombinant Human DGKE is a valuable tool for studying the role of DAG in cellular processes. It can be used to investigate the function of DGKE in different pathways and its interaction with other proteins. Recombinant Human DGKE can also be used to study the effects of mutations or genetic variations in the enzyme, providing insights into its structure and function.
Abnormalities in the DAG metabolism have been linked to various diseases, including cancer, diabetes, and neurological disorders. Recombinant Human DGKE has shown potential as a therapeutic target for these diseases. Its ability to regulate DAG levels and lipid signaling pathways makes it a promising candidate for drug development.
Recombinant Human DGKE can also be used as a diagnostic tool for certain diseases. Abnormal levels of DGKE have been observed in patients with certain types of cancer and diabetes, making it a potential biomarker for disease diagnosis and monitoring.
Recombinant Human DGKE has been identified as an antigen in various pathogens, including bacteria and viruses. This makes it a potential target for vaccine development, as it can induce an immune response against these pathogens.
Recombinant Human DGKE is a crucial enzyme involved in the regulation of lipid signaling pathways. Its structure and activity make it a valuable tool for research and potential therapeutic applications. With its diverse applications and potential as a drug target, Recombinant Human DGKE holds great promise for future advancements in the field of lipid metabolism and related diseases.
ProteoGenix catalogue number ARO-P13651. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 31.09 kDa; Tag: N-Terminal His Tag; Fragment: Leu243-Gly502; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
